Effect of rD-mPGPtide on Progenitor Cell Origin in the Haploidentical and MHC Class II-Disparate Strain Combinations
| Strain Combination . | Treatment . | Phenotype of CFU-GM (% donor/host) . |
|---|---|---|
| (B6D2)F1 → (B6CB)F1 (750 cGy) | PBS | 9.7/91.3 |
| rD-mPGPtide | 97.1/0.2 | |
| Anti-CD4 MoAb | 97.8/0.5 | |
| bm12 → B6-Ly5.2 (650 cGy) | PBS | 0.8/92.0 |
| rD-mPGPtide | 85.7/2.3 | |
| Anti-CD4 MoAb | 90.2/1.5 |
| Strain Combination . | Treatment . | Phenotype of CFU-GM (% donor/host) . |
|---|---|---|
| (B6D2)F1 → (B6CB)F1 (750 cGy) | PBS | 9.7/91.3 |
| rD-mPGPtide | 97.1/0.2 | |
| Anti-CD4 MoAb | 97.8/0.5 | |
| bm12 → B6-Ly5.2 (650 cGy) | PBS | 0.8/92.0 |
| rD-mPGPtide | 85.7/2.3 | |
| Anti-CD4 MoAb | 90.2/1.5 |
Progenitor cell origin was determined by dual-color flow cytometry using the following MoAb pairs: PE-anti-H2Kd and FITC-anti-H2Kk [(B6D2)F1 → (B6CB)F1 ]; SA-PE-biotin-anti-CD45.2 (anti-Ly5.2) and FITC-anti-CD45.1 (anti-Ly5.1) (bm12 → B6-Ly5.2). CFU-GM originating from the bm12 → B6-Ly5.2 and the (B6D2)F1 → (B6CB)F1 strain combinations were phenotyped on days 8 and 10, respectively, after in vitro plating. The data are from a representative of two separate experiments and the values presented are the percentage of positive-staining cells derived from host or donor origin. The data in all rD-mPGPtide and anti-CD4 MoAb treatment groups were significantly different from those in the PBS control group, P ≤ .001.